ROLE OF CERTAIN GROWTH FACTORS IN INSULIN RESISTANCE IN A SAMPLE OF IRAQI OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS ISRAA MUHAMMAD MUBARAK ALDOURI, JABBAR HAMEED YENZEEL
DOI:
https://doi.org/10.29121/shodhkosh.v7.i10s.2026.8121Keywords:
Obesity, Type 2 Diabetes Mellitus, Insulin Resistance, BMI, FGF21, TGF-βAbstract [English]
Background: Obesity and type 2 diabetes mellitus (T2DM) are closely interconnected metabolic disorders, with insulin resistance representing a key underlying mechanism. Growth factors such as fibroblast growth factor-21 (FGF21) and transforming growth factor-beta (TGF-β) have been increasingly implicated in metabolic dysregulation; however, their roles in obese Iraqi patients remain insufficiently explored.
Methods: This cross-sectional study included 100 participants divided into three groups: obese patients with T2DM (n=35), obese non-diabetic individuals (n=35), and healthy controls (n=30). Clinical and biochemical parameters, including body mass index (BMI), fasting blood glucose (FBG), and glycated hemoglobin (HbA1c), were measured. Serum levels of FGF21 and TGF-β were determined using enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using SPSS, with significance set at p<0.05.
Results: Significant increases (p≤0.01) in FBG and HbA1c were observed in the obese with T2DM group compared to other groups. Serum FGF21 and TGF-β levels were significantly elevated in obese patients with T2DM (795.92±126.22 pg/ml and 2360.25±204.51 pg/ml, respectively) compared to controls. No significant differences were observed between obese non-diabetic and control groups. These findings indicate progressive metabolic deterioration associated with insulin resistance.
Conclusion: Elevated FGF21 and TGF-β levels are strongly associated with obesity complicated by T2DM and may reflect underlying metabolic stress, inflammation, and fibrosis. These growth factors could serve as potential biomarkers for insulin resistance and disease progression in obese individuals.
References
Ahmed, B., Sultana, R., & Greene, M. W. (2021). Adipose tissue and insulin resistance in obese. Biomedicine & Pharmacotherapy, 137, 111315. https://doi.org/10.1016/j.biopha.2021.111315
Al-Lami, R. S. S., & Al-Hilfy, J. H. Y. (2025). Role of interleukins-8, -17 and -22 in Iraqi postmenopausal women with osteoporosis. Cytokine, 187, 156853. https://doi.org/10.1016/j.cyto.2024.156853
Alsaffar, S. F., Jumaa, H. M., & Baqer, N. N. (2024). Detection of leptin and ghrelin hormones and the expression of their receptors in Iraqi obese individuals. Iraqi Journal of Science, 36–42. https://doi.org/10.24996/ijs.2024.65.1.4
American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care, 47(Suppl. 1), S1–S350.
Ansari, S., Khoo, B., & Tan, T. (2024). Targeting the incretin system in obesity and type 2 diabetes mellitus. Nature Reviews Endocrinology, 20(8), 447–459. https://doi.org/10.1038/s41574-024-00979-9
Blüher, M., & Schwarz, P. (2023). Metabolically healthy obesity: Mechanisms and clinical implications. Nature Reviews Endocrinology, 19(3), 135–149.
Budi, E. H., et al. (2021). Transforming growth factor-β in adipose tissue fibrosis and metabolic dysfunction. Trends in Endocrinology & Metabolism, 32(12), 1033–1047.
Callan, A., Jha, S., Valdez, L., Baldado, L., & Tsin, A. (2024). TGF-β signaling pathways in the development of diabetic retinopathy. International Journal of Molecular Sciences, 25(5), 3052. https://doi.org/10.3390/ijms25053052
Castañé, H., et al. (2025). Circulating FGF21 and its association with visceral adiposity and insulin resistance. Metabolism.
De Sousa-Coelho, A. L., et al. (2023). FGF21 in metabolic disease: From physiology to therapeutic applications. Endocrine Reviews, 44(2), 189–221.
DeFronzo, R. A., et al. (2021). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 7, 1. https://doi.org/10.1038/nrdp.2015.19
Halter, J. B. (2011). Aging and insulin secretion. In E. J. Masoro & S. N. Austad (Eds.), Handbook of the biology of aging (7th ed., pp. 373–384). Academic Press. https://doi.org/10.1016/B978-0-12-378638-8.00017-8
Hotamisligil, G. S. (2017). Inflammation, metaflammation and immunometabolic disorders. Nature, 542, 177–185. https://doi.org/10.1038/nature21363
International Diabetes Federation. (2023). IDF diabetes atlas (10th ed.).
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes. The Lancet, 383(9922), 1068–1083. https://doi.org/10.1016/S0140-6736(13)62154-6
Kalyani, R. R., Golden, S. H., & Cefalu, W. T. (2017). Diabetes and aging: Unique considerations and goals of care. Diabetes Care, 40(4), 440–443. https://doi.org/10.2337/dci17-0005
Karastergiou, K., et al. (2022). Sex differences in human adipose tissues. Biology of Sex Differences, 13(1), 35. https://doi.org/10.1186/s13293-022-00440-4
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2024). Sex and gender differences in type 2 diabetes mellitus. Endocrine Reviews, 45(1), 1–32.
Lee, S. H., Park, S. Y., & Choi, C. S. (2022). Insulin resistance: From mechanisms to therapeutic strategies. Diabetes & Metabolism Journal, 46(1), 15–37. https://doi.org/10.4093/dmj.2021.0280
Li, H., et al. (2018). Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nature Communications, 9, 272. https://doi.org/10.1038/s41467-017-02677-9
Lu, X., et al. (2024). Type 2 diabetes mellitus in adults: Pathogenesis, prevention and therapy. Signal Transduction and Targeted Therapy, 9(1), 262. https://doi.org/10.1038/s41392-024-01951-9
Luli, M., et al. (2023). The implications of defining obesity as a disease: A report from the Association for the Study of Obesity 2021 annual conference. EClinicalMedicine, 58, 101962. https://doi.org/10.1016/j.eclinm.2023.101962
Malone, J. I., & Hansen, B. C. (2019). Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite? Pediatric Diabetes, 20(1), 5–9. https://doi.org/10.1111/pedi.12787
Mansour, M. A., Caputo, V. S., & Aleem, E. (2021). Highlights on selected growth factors and their receptors as promising drug targets. Biochemistry and Cell Biology, 99(6), 667–679. https://doi.org/10.1016/j.biocel.2021.106087
Marcelin, G., Silveira, C., Martins, V., & Clément, K. (2022). Adipose tissue fibrosis in obesity: Etiology and challenges. Annual Review of Physiology, 84, 135–155. https://doi.org/10.1146/annurev-physiol-060721-092930
Patt, M., Karkossa, I., Krieg, L., Massier, L., Makki, K., Tabei, S., et al. (2024). FGF21 and its underlying adipose tissue-liver axis inform cardiometabolic burden and improvement in obesity after metabolic surgery. EBioMedicine, 110. https://doi.org/10.1016/j.ebiom.2024.105458
Peterseim, C. M., Jabbour, K., & Mulki, A. K. (2024). Metabolic syndrome: An updated review on diagnosis and treatment for primary care clinicians. Journal of Primary Care & Community Health. https://doi.org/10.1177/21501319241309168
Petersen, M. C., & Shulman, G. I. (2018). Mechanisms of insulin action and insulin resistance. Physiological Reviews, 98(4), 2133–2223. https://doi.org/10.1152/physrev.00063.2017
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., et al. (2023). Obesity and type 2 diabetes mellitus: Connections in epidemiology, pathogenesis, and treatments. Frontiers in Endocrinology, 14, 1161521. https://doi.org/10.3389/fendo.2023.1161521
Siddiqui, S., & Singh, N. (2026). ROLE OF VLSI IN MODERN BIOMEDICAL APPLICATIONS. International Journal of Engineering Science Technologies, 10(1), 10–16. https://doi.org/10.29121/ijoest.v10.i1.2026.732
Stone, W. L., Leavitt, L., & Varacallo, M. (2021). Physiology, growth factor. In StatPearls. StatPearls Publishing.
Tan, H., et al. (2023). Targeting fibroblast growth factor 21 in metabolic diseases. International Journal of Biological Sciences, 19(1), 66–83. https://doi.org/10.7150/ijbs.73936
Tsurutani, Y., et al. (2011). The roles of transforming growth factor-beta and Smad3 signaling in adipocyte differentiation and obesity. Biochemical and Biophysical Research Communications, 407, 68–73. https://doi.org/10.1016/j.bbrc.2011.02.106
Wen, H., et al. (2022). Role of TGF-β signaling in obesity and metabolic diseases. Frontiers in Endocrinology, 13, 845000.
World Health Organization. (2024). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
World Health Organization. (2025). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
World Obesity Federation. (2022). World obesity atlas 2022. https://data.worldobesity.org/publications/?cat=15
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Israa Muhammad Mubarak Al-Douri, Jabbar Hameed Yenzeel
This work is licensed under a Creative Commons Attribution 4.0 International License.
With the licence CC-BY, authors retain the copyright, allowing anyone to download, reuse, re-print, modify, distribute, and/or copy their contribution. The work must be properly attributed to its author.
It is not necessary to ask for further permission from the author or journal board.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
